714TiP A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 34; p. S494
Main Authors Luen, S.J., Ahern, E.S., Berger, C., Desai, J., Frentzas, S., Gan, H., Gualandi, M., Markman, B., Millward, M., Rafiei, A., Tran, B., Renner, C.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2023
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.09.1900